The Magazine for Sleep Professionals
Wednesday, July 8, 2026
Dental Sleep Medicine | Sleep Disorders | Testing Modalities & Diagnostics | Patient Health | Pharmaceuticals | Research/Studies
Ognomy Sleep, announced the closing of a $20 million Series A financing round led by Catalyst Investors, with participation from Blue Heron Capital. The round also included new and follow-on investments from Impellent Ventures, LaunchNY, Excell and Upstate Biotech Ventures, University of Buffalo, and strategic partners who have supported the company’s […]
Recently published study results demonstrate the efficacy of LivaNova Plc’s aura6000 System in treating moderate to severe obstructive sleep apnea (OSA). Published in Annals of Internal Medicine, the full 12-month results from the company’s OSPREY randomized controlled trial (RCT) demonstrate the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality. Overall, the study authors concluded that pHGNS for OSA yielded clinically significant improvements versus […]
Sleep medicine is at a critical point. Demand is rising, the science is expanding, and too few specialists are available to meet the need. The U.S. has just 7,500 board-certified sleep specialists to serve a population of 325 million—many of whom have sleep disorders with complex comorbidities that require ongoing, […]
ŌURA maker of the world’s most trusted smart ring, Oura Ring, and LillyDirect, Eli Lilly and Company’s digital health platform designed to connect people living with chronic conditions to the care, support, and prescribed medicines they need, today announced a collaboration enabling savings on the Oura Ring sizing kit. The […]
ProSomnus Sleep Technologies (“ProSomnus”), pioneer of Smart Sleep Medicine™, and MonitAir, LLC (“MonitAir”), the premier digital health and tele-monitoring platform for sleep medicine announced a collaboration to support connected, longitudinal and personalized care for patients with obstructive sleep apnea (OSA). Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ […]
Jazz Pharmaceuticals plc delivered 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic […]
Inspire Medical Systems, Inc. participated in SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS) on June 14–17 in Baltimore, Maryland. SLEEP is the premier global forum for sleep medicine and research, jointly hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research […]
New data presented by Takeda at SLEEP 2026 this week continues to build the case for oveporexton (TAK-861) as a potential disease-modifying treatment for narcolepsy type 1 (NT1). Oveporexton is designed to address the root cause of the disease, targeting the underlying orexin deficiency responsible for NT1. Results from two pivotal […]
Huxley Medical, a commercial-stage medical technology company expanding access to sleep apnea testing across health systems, cardiology, and primary care, today introduced two additions to its SANSA® platform: SANSA GO™, a point-of-care enrollment model that enables clinics to dispense SANSA at patient visits, and hypoxic burden, an additional measure of […]
Wesper unveiled its multi-tier sleep diagnostic ecosystem at SLEEP 2026, the annual meeting of the Associated Professional Sleep Societies. The ecosystem brings two purpose-built diagnostic pathways, Wesper Lab and Wesper Lite, onto one platform, one patient record, and one interpretation pipeline, so physicians can match the right test to the right […]
